Oxygenating Hope: The Future of ECMO Research in India

Oxygenating Hope: The Future of ECMO Research in IndiaThe integration of Extracorporeal Membrane Oxygenation (ECMO) into the Indian critical care landscape has undergone a paradigm shift, transitioning from a specialized care in elite tertiary centers to a more widely recognized component of advanced life support.This evolution was accelerated by the COVID-19 pandemic, which necessitated the rapid scaling of respiratory support technologies.In a healthcare system characterized by extreme diversity in infrastructure, a high burden of infectious diseases 1 , and significant financial barriers, there is an urgent need to define and pursue research priorities specifically tailored to the Indian environment (Fig. 1).A foundational priority is the generation of high-quality, locally relevant clinical evidence.Currently, Indian ECMO protocols are derived from countries where patient demographics, comorbidities, and healthcare delivery systems differ substantially.To bridge this gap, there is an utmost need to move beyond retrospective, single-center studies toward prospective studies.Establishing a robust national ECMO registry is essential; such a platform would allow for the systematic collection of data on patient outcomes, enabling the development of evidence-based guidelines that reflect the biological and logistical realities of treating ECMO patients in India. 2 The challenges of patient selection and the timing of initiation are particularly different in the Indian setting.Unlike in many Western systems, patients in India often present with advanced organ failure due to delays in referral, lack of transport logistics, or initial financial hesitation.Research must focus on identifying affordable, point-of-care biomarkers and simplified clinical scoring systems could provide clinicians with objective tools to decide when ECMO is truly indicated, avoiding both the futility of late initiation and the unnecessary costs of premature intervention. 3harmacological management represents another critical research frontier in patients needing ECMO, especially concerning the high prevalence of multidrug-resistant (MDR) infections in Indian intensive care units (ICUs).The interaction between the ECMO circuit and drug pharmacokinetics-specifically for antibiotics and anticoagulants-is complex and poorly understood in the context of Indian body compositions and disease burdens.Research is needed to establish optimized dosing regimens for antimicrobials to combat antibiotic resistance effectively during extracorporeal support.Similarly, studies should investigate standardized anticoagulation protocols that remain safe and effective when monitored with more basic, widely available laboratory tools.Technological innovation and cost-effectiveness are perhaps the most vital pillars for the long-term sustainability of ECMO in India.The prohibitive cost of imported consoles and disposable circuits remains a primary barrier to equity in care.Research and Fig. 1: Advancing affordable, innovative ECMO care for better patient outcomes in India.